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Abstract
Background: Aneuploidy is a leading cause of repeat implantation failure and recurrent miscarriages. Preimplantation
genetic screening (PGS) enables the assessment of the numeral and structural chromosomal errors of embryos before
transfer in patients undergoing in vitro fertilization. Array comparative genomic hybridization (aCGH) has been
demonstrated to be an accurate PGS method and in present thought to be the gold standard, but new technologies,
such as next-generation sequencing (NGS), continue to emerge. Validation of the new comprehensive NGS-based
24-chromosome aneuploidy screening technology is still needed to determine the preclinical accuracy before it might
be considered as an alternative method for human PGS.
Results: In the present study, 43 human trophectoderm (TE) biopsy samples and 5 cytogenetically characterized cell
lines (Coriell Cell Repositories) were tested. The same whole genome amplified product of each sample was blindly
assessed with Veriseq NGS and Agilent aCGH to identify the aneuploidy status. The result showed that the NGS identified
all abnormalities identified in aCGH including the numeral chromosomal abnormalities (again or loss) in the embryo
samples and the structural (partial deletion and duplication) in the Coriell cell lines. Both technologies can identify a
segmental imbalance as small as 1.8 Mb in size. Among the 41 TE samples with abnormal karyotypes in this study, eight
(19.5 %) samples presented as multiple chromosome abnormalities. The abnormalities occurred to almost all
chromosomes, except chromosome 6, 7, 17 and Y chromosome.
Conclusions: Given its reliability and high level of consistency with an established aCGH methodology, NGS has
demonstrated a robust high-throughput methodology ready for extensive clinical application in reproductive medicine,
with potential advantages of reduced costs and enhanced precision. Then, a randomized controlled clinical trial
confirming its clinical effectiveness is advisable to obtain a larger sequencing dataset and more evidence for the
extensive use of NGS-based PGS.
Keywords: Preimplantation genetic screening, Next-generation sequencing, Aneuploidy screening, Array
comparative genomic hybridization, Blastocyst
Background
Successful in vitro fertilization-embryo transfer (IVF-ET)
is based partially on selection of viable embryos [1].
However, it is well known that many women fail to
achieve a pregnancy even after transfer of good quality
embryos. It had been suspected that a high incidence of
chromosome aneuploidy in human oocytes and/or em-
bryos might cause low implantation and pregnancy rates
[2]. Aneuploidy is also a leading cause of miscarriages and
congenital birth defects [3, 4]. The high frequency of an-
euploidy during preimplantation development has led to
the suggestion that embryos should be tested for chromo-
somal abnormalities before transfer to the uterus [5].
Assisted reproduction technology (ART) has incorpo-
rated genetic tools for genetic testing of preimplantation
embryos, which is performed in patients with high risk for
monogenic disorders [6] or chromosomal structural abnor-
malities [7]. Preimplantation genetic diagnosis (PGD) for
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aneuploidy screening of embryos derived from patients
undergoing IVF, also termed preimplantation genetic
screening (PGS), enables the assessment of the numeral
and structural chromosomal constitution of embryos
before transfer. It has been applied to treat patients with
increased risk for aneuploid embryos, and then intro-
duced into clinical practice to improve the chance of
healthy conceptions after infertility treatment with poor
prognoses, such as advanced maternal age, repeated im-
plantation failure, and recurrent miscarriage [8, 9]. A
latest research reviewed literatures on PGS for aneu-
ploidy with analysis of all chromosomes showed that
embryo implantation rates could be significantly in-
creased by the transfer screened euploid embryos [10].
To improve ART success rates and reduce miscarriage
rates, 24-chromosome copy number analysis, a test that is
noninvasive, rapid, and sufficiently low cost for application
to all patients, may be effective. The first molecular cyto-
genetic technique to be applied to interphase nuclei
spread on slides was fluorescence in situ hybridization
(FISH) with the use of specific probes for the chromo-
somes most commonly involved in aneuploidy. However,
FISH-based PGS results were untenable by some reports
[11, 12]. A large number of prospective randomized clin-
ical trials (RCTs) have consistently failed to show any im-
provement in delivery rates with the use of FISH-based
PGS [13], although a recent RCT has reported a signifi-
cant increase in live birth rates in patients of advanced
maternal age [14]. This was attributed to particularly the
limited number of chromosomes analyzed. Therefore, the
focus has now shifted to new technologies that allow all
24 chromosomes to be analyzed to provide a more accur-
ate assessment of embryos.
Today, development of a range of molecular genetic tech-
nologies allows copy number analysis for all 24 chromo-
somes in single or small numbers of cells, such as biopsies
from preimplantation embryos. A variety of methodologies
for 24-chromosome analysis have been developed, includ-
ing array comparative genomic hybridization (aCGH) [15],
single-nucleotide polymorphism microarrays (SNP) [16],
and quantitative polymerase chain reaction (Q-PCR) [17].
Array CGH was the first technology to be widely used for
24-chromosome copy number analysis [18] around the
world despite the relatively high cost of testing multiple
samples. This method uses microarray technology to de-
liver comprehensive aneuploidy screening through its abil-
ity to detect imbalances in any of the 24 chromosomes
rather than the limited chromosome assessment achievable
by FISH [15, 18]. Higher pregnancy and live birth rates than
previously reported for FISH-based testing have been re-
ported [15].
The latest advances in next-generation sequencing
(NGS) methods are revolutionizing the way biological re-
search is conducted and clinical diagnosis is performed.
PGS is different from other clinical diagnosis, small
amount of embryo cells, accurate data, simple data ana-
lysis, reliable instrument support, cost effectiveness and
scalability are crucial factors to consider. Chromosomal
copy number assessment based on NGS may offer several
advantages to aCGH including reduced DNA sequencing
cost, enhanced detection of partial or segmental aneu-
ploidies as a result of the potential increase in chromo-
somal analysis resolution, the potential automation of the
sequencing library preparation to minimize human errors,
reduce hands-on time, and enable higher throughput and
consistency [19–22].
In addition, the focus in the PGS field has now shifted
from day 3 single blastomere biopsy to day 5/6 troph-
ectoderm (TE) sampling and the use of comprehensive
chromosome screening technologies, in order to pro-
vide a more accurate assessment of the reproductive po-
tential of embryos. With the use of NGS with TE
samples from blastocyst biopsies, both whole chromo-
some aneuploidy and segmental chromosome imbal-
ances could be detected [21].
Potential improvements have been reported in human
ART with the transfer of embryos examined with current
comprehensive aneuploidy screening methods [19, 23–25].
However, application of the new comprehensive technolo-
gies is still needed to determine the preclinical accuracy
before they might be considered within the standard of
care in reproductive medicine. The present study inves-
tigated the accuracy of NGS technology for comprehen-
sive chromosome screening as a preclinical step before
its clinical application in the diagnosis of chromosomal
aneuploidy on embryos at blastocyst stage.
Results
Workflows of NGS-based PGS and aCGH-based PGS
Workflows of NGS-based PGS and aCGH-based PGS
are summarized in Table 1. As shown in Table 1, the
procedures for embryo biopsy and sample collection are
similar between aCGH-based PGS and NGS-based PGS
except that a reference genomic DNA (gDNA) sample is
necessary for aCGH. After sample collection, WGA is
necessary for both aCGH and NGS, and it took three
hours to process WGA. After WGA, the procedures are
totally different between two technologies. As shown in
Table 1, one of the most time-consuming procedures for
aCGH is DNA hybridization to array slides. This process
has been significantly improved and the time has been
reduced from previous ~15 hrs to current 2 hrs. This
improvement has made aCGH-based PGS can be done
within 8 hrs. However, for NGS-based PGS, the most
time-consuming procedure is DNA sequencing. Al-
though DNA sequencing time has been dramatically re-
duced during the past few years, it still needs ~6 hrs to
complete the DNA sequencing for current PGS purpose.
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Due to this reason, the procedures for NGS-based PGS
can be done in ~14 hrs.
Consistency of aneuploidy screening with NGS and aCGH
To test the feasibility of using NGS for PGS, a total of
43 TE samples biopsied from human blastocysts were
tested. Successful results were obtained by NGS in all
samples (100 %) included in the experiment. As showed
in Table 2, when the NGS and aCGH aneuploidy results
were compared, it was found that the NGS identified all
abnormalities identified in aCGH. The predictive value
of the NGS-based 24-chromosome aneuploidy screening
protocol was 100 % for a normal (2/2) and 100 % for ab-
normal (41/41) index results. There were no false negative
diagnoses for aneuploid chromosomes or embryos, or
inaccurate predictions of gender. Comparative graph ex-
amples of NGS and aCGH results are shown in Fig. 1, in
which samples with monosomy and trisomy were exhib-
ited. All abnormal samples showed balanced, structural
abnormalities, i.e. gain or loss of entire chromosomes.
Segmental imbalance analysis with NGS and aCGH
In order to further examine partial (imbalanced) chromo-
some abnormalities, we further tested 5 cytogenetically
characterized cell lines with both aCGH and NGS. These
cells lines have known chromosomal segmental break-
points and sizes, and have been used for validation of dif-
ferent cytogenetic protocols. As shown in Table 3, NGS
method identified the same microdeletions and amplifica-
tions of 5 Coriell cell lines as aCGH method. The sizes of
the segmental errors were from 1.19 Mb to 3.89 Mb in the
present study. As shown in Table 3 and Fig. 2, the smallest
segment detected by both methods was 1.81 Mb. A sam-
ple (second chromosomal error in the sample #5) with
1.19 Mb microdeletion was not detected by both methods.
The detailed breakpoints and sizes of segments in the
chromosomes from each cell line were also showed in
Table 3.
Multiple abnormalities on different chromosomes
Among the 41 TE cell samples with abnormal karyotypes
in this study, eight (19.5 %) samples (sample # 9, 33, 34,
35, 38, 40, 41 and 43 in Table 2) presented as multiple
chromosome abnormalities. The abnormalities occurred
to almost all chromosomes, except chromosome 6, 7, 17
and Y chromosome. However, the incidence of abnormal-
ity was different among chromosomes (Fig. 3). Chromo-
some errors exceeding three times happened to eight
chromosomes, and abnormality of chromosome 22 oc-
curred up to eight times.
Discussion
Chromosomal abnormalities may arise during germ cell
and/or preimplantation embryo development. The em-
bryonic chromosomes have direct impacts on embryo
implantation and the successful development of those
embryos into healthy babies. Recent years, NGS is an
emerging technology that provides unprecedented high-
throughput, highly parallel, and base-pair resolution data
for embryo genetic analysis, but it is still under develop-
ment for extensively clinical application to PGS. In the
present preclinical study, we performed a validation
study to determine the accuracy of an NGS-based 24-
chromosome screening protocol. Trophectoderm cells
from human blastocysts as well as the cytogenetically
characterized cell lines with known chromosomal errors
were analyzed and compared between aCGH and NGS.
Our results provided a complete consistency for samples
Table 1 Comparison of workflows using NGS and aCGH for 24-chromosome copy number analysis
aCGH NGS
1 Embryo biopsy NA Embryo biopsy
2 Sample collection Reference gDNA (+10 min) Sample collection
3 WGA (3 hrs) WGA (3 hrs) WGA (3 hrs)
4 Labeling of amplified DNA (1 hrs) Pooling and labeling of amplified DNA (1 hrs) Qualification and dsDNA input dilution (20 min)
5 Preparation of labeled DNA (1 hrs) Preparation of labeled DNA (1 hrs) Tagmentation (20 min)
6 Hybridization to array (2 hrs) PCR amplification (50 min)
7 Washing and Scanning (20 min) PCR clean-up (30 min)
8 Cytogenomics analysis (40 min) Library normalization (30 min)
9 NA Library pooling and loading (10 min)
10 N/A Sequencing (6 hrs)
11 N/A Bioinformatics analysis (2 hrs)
Total hrs ~8 hrs ~14 hrs
NGS: next generation sequencing
aCGH: array comparative genomic hybridization
WGA: whole-genome amplification
NA: not applicable
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between two methods, indicating the accuracy and reli-
ability of NGS technology for human PGS.
Clinical validation of new technologies to be applied for
embryo diagnosis is particularly challenging. Previous re-
sults also showed that NGS was highly sensitive and spe-
cific for detection of aneuploidy, and segmental imbalances
in 24-chromosome screening [19, 24, 25]. In addition to the
validation of NGS in the detection of whole-chromosome
aneuploidies in our study, cytogenetically characterized cell
lines were detected meanwhile and showed that the NGS
protocol was capable of accurately quantifying chromo-
some imbalances down to 1.8 Mb in size, indicating that
diagnosis of partial aneuploidies is well within the ability of
this technology.
Any strategy available for aneuploidy testing has to
balance the benefits of identifying euploid embryos with
the potential costs to the embryo of any invasive biopsy
or any false positive and negative test results. Nowadays,
largely because of efforts required to complete the Human
Genome Project, DNA sequencing has undergone a steady
transformation with still-ongoing developments of high-
throughput sequencing machines for which the cost per re-
action is falling drastically. The National Human Genome
Research Institute has tracked the costs associated with
DNA sequencing (available at: www.genome.gov/sequen
cingcost, accessed February 2015). The figure in the website
showed that significant cost reduction was exhibited begin-
ning in 2008, when sequencing centers moved from
Sanger-based to NGS-based DNA sequencing technolo-
gies. The overall efficacy of PGS might be potentially
further improved and eventually the advantages of NGS
will be brought to PGS patients.
There are numerous advantages to using NGS for 24-
chromosome aneuploidy screening. NGS-based method for
copy number analysis is likely to be the most accurate and
informative, because they use sequence data from thou-
sands of loci across each chromosome. The parallel nature
of NGS data provides a unique opportunity to evaluate
multiple genomic loci and multiple samples on one chip.
That is to say, DNA samples from different patients requir-
ing sequence data in different genomic loci could also be
evaluated on the same sequencing chip [26]. These features
make NGS useful for evaluation of aneuploidy, monogene
disorders and translocations simultaneously from the same
Table 2 Chromosomes results of trophectoderm cells detected
by next generation sequencing and array comparative genomic
hybridization based preimplantation genetic screening
Samples NGS karyotype Array karyotype Detected
1 47, XY, +15 arr (15) × 3 Yes
2 47, XY, +4 arr (4) × 3 Yes
3 45, XO arr (X) × 1 Yes
4 45, XY, -22 arr (22) × 1 Yes
5 47, XXY arr (X) × 2, (Y) × 1 Yes
6 48, XXY, +15 arr (X) × 2, (Y) × 1, (15) × 3 Yes
7 47, XX, +22 arr (22) × 3 Yes
8 45, XY, -21 arr (21) × 1 Yes
9 42, XY, -4, -5, -18, -19 arr (4) × 1, (5) × 1,
(18) × 1,(19) × 1
Yes
10 47, XY, +15 arr (15) × 3 Yes
11 47, XY, +20 arr (20) × 3 Yes
12 47, XY, +16 arr (16) × 3 Yes
13 47, XY, +22 arr (22) × 3 Yes
14 47, XXY arr (X) × 2, (Y) × 1 Yes
15 47, XX, +13 arr (13) × 3 Yes
16 45, XY, -10 arr (10) × 1 Yes
17 47, XY, +5 arr (5) × 3 Yes
18 47, XY, +14 arr (14) × 3 Yes
19 45, XY, -8 arr (8) × 1 Yes
20 45, XO arr (X) × 1 Yes
21 45, XO arr (X) × 1 Yes
22 45, XX, -16 arr (16) × 1 Yes
23 45, XX, -21 arr (21) × 1 Yes
24 45, XX, -19 arr (19) × 1 Yes
25 45, XY, -3 arr (3) × 1 Yes
26 45, XY, -22 arr (22) × 1 Yes
27 45, XY, -4 arr (4) × 1 Yes
28 46, XX arr (1-22,X) × 2 Yes
29 47, XX, +19 arr (19) × 3 Yes
30 46, XY arr (1-22) × 2, (XY) × 1 Yes
31 47, XY, +3 arr (3) × 3 Yes
32 45, XY, -1 arr (1) × 1 Yes
33 46, XY, +15, -16 arr (15) × 3, (16) × 1 Yes
34 46, XY, +21, +22 arr (21) × 3, (22) × 3 Yes
35 48, XY, +11, +14, -19, +22 arr (11) × 3, (14) × 3,
(22) × 3, (19) × 1
Yes
36 47, XY, +10 arr (10) × 3 Yes
37 45, XX, -2 arr (2) × 1 Yes
38 46, XY, +4, -19 arr (4) × 3, (19) × 1 Yes
39 45, XY, -16 arr (16) × 1 Yes
Table 2 Chromosomes results of trophectoderm cells detected
by next generation sequencing and array comparative genomic
hybridization based preimplantation genetic screening
(Continued)
40 48, XY, +19, +22 arr (19) × 3, (22) × 3 Yes
41 46, XY, +12, -14 arr (12) × 3, (14) × 1 Yes
42 45, XX, -9 arr (9) × 1 Yes
43 44, XX, -21, -22 arr (21) × 1, (22) × 1 Yes
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biopsy without the need for multiple technological plat-
forms [26].
Compared with aCGH, a control sample (reference
gDNA sample) is not necessary for NGS. NGS does not re-
quire a sample-reference model for data normalization. A
specific algorithm step is used to normalize the data and
remove any bias for the sample preparation. NGS operates
on a linear copy number scale instead of the logarithmic ra-
tio scale of array experiments. Therefore, the concept of
XY separation does not apply as it does for microarray.
The NGS algorithms have been developed for whole-
chromosome calling. In high quality samples, it is
Table 3 Chromosomes results of Coriell cell lines with segmental imbalances
Samples NGS karyotype aCGH karyotype Breakpoints Size
1 47, XX, Dup (16) (p13.3) 47, XX, Dup (16) (p13.3) 764-3664353 3.36 Mb (detected)
2 46, XX, Del (5) (q35.3) 46, XX, Del (5) (q35.3) 178022586-180331967 2.53 Mb (detected)
3 46, XY Del (9) (p24.3) 46, XY Del (9) (p24.3) 36586-1846893 1.81 Mb (detected)
4 45, XX, Del (13) (q11q12.11) 45, XX, Del (13) (q11q12.11) 17943627-21831429 3.89 Mb (detected)
5 46, XX, Dup (6) (p25.3) 46, XX, Dup (6) (p25.3) 94648-2289621 2.19 Mb (detected)
Del 14(q)32.12q Del 14(q)32.12q 91720288-92918797 1.19 Mb (Not detected)
NGS: next generation sequencing
aCGH: array comparative genomic hybridization
Fig. 1 Representation samples of copy number changes observed in samples biopsied from blastocysts. Left panel: PGS results from array comparative
genomic hybridization (aCGH) analysis; right panel: PGS results from next generation sequencing (NGS) analysis. X-axis indicate chromosome numbers
(1-22, X and Y) and y-axis indicate chromosome copy number assignments (0, 1, 2, 3, or 4). The gains (copy number state >2) and losses (copy number
state <2) of chromosomes in the right panel obtained with NGS exactly match those in the left panel obtained with aCGH. (I) Top left and right charts
show a monosomy X from sample #3 in Table 2. (II) Middle left and right charts show monosomy 4, 5, 18 and 19 from sample #9 in Table 2. (III) Bottom
left and right charts show trisomy 11, 14, 22 and monosomy19 from sample #35 in Table 2. Arrows indicate the locations of abnormal chromosomes
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sometimes possible to see subchromosmal imbalances.
This will be possible if multiple cells are biopsied from
blastocysts.
NGS has an increases dynamic range compared to 24
chromosome array and this applies to sources of noise
present in the data. The main sources of noise originate
from poor sample quality and amplification artifacts, in-
cluding suboptimal embryo biopsy, DNA nicking, in-
complete cell lysis, cells undergoing apoptosis, the
presence of PCR inhibitors in media, and protocol devia-
tions. These effects are typically more prevalent in single
cell biopsy at day 3 than TE samples where greater
quantities of starting materials are available. A failed
amplification can be detected in most cases by observing
the lack of a DNA smear in an agarose gel run as a part
of the Sureplex amplification protocol.
Because the dynamic range of NGS-based PGS is
higher than microarray, the copy number changes are
clearly distinguishable from the normal background in
good samples. It also means that any noise will be more
apparent and failed samples will be easy to identify. Mo-
saicism is more clearly visible in NGS-based PGS.
No diagnosis (no data) in samples with aCGH can be
as high as 5 % with samples from blastocyst biopsy [27],
and the rate may be higher if single cells are used from
day 3 blastomere biopsy [28]. As mentioned about, this
Fig. 2 Examples of segmental imbalance detection selected from Coriell cell lines by next-generation sequencing (right panel) compared with array
comparative genomic hybridization (left panel). Arrows in the right panel indicate locations of partial chromosomal imbalances. Blue and red boxes
(indicated by arrows) in the left panel indicate same partial chromosomal imbalances (duplication or deletion), respectively. Only abnormal chromosomal
segment (not all 24 chromosomes) are showed in the left panel. (I) Top left and right charts show a sample with a 2.19-Mb segmental duplication on the
short arm of chromosome 6 from sample #5 in Table 3. (II) Middle left and right charts show a sample with a 2.53-Mb segmental deletion on the long arm
of chromosome 5 from sample #2 in Table 3. (III) Bottom left and right charts show a sample with a 1.81-Mb segmental deletion on the short arm of
chromosome 9 from sample #3 in Table 3
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may be due to many reasons, and one of the major rea-
sons is sample quality. However, for blastocysts biopsy,
multiple cells are usually separated from embryos, and
greater amount of DNA would increase the amplification
and reduce noises, thus improve the diagnosis rate. In the
present study, we got diagnosis results from all samples
tested, indicating the effectiveness of NGS-based PGS
technology for samples biopsied from blastocyst.
As a general limitation, same as microarray, NGS-
based PGS is not intended to detect polyploidies. Also,
calling of low-level mosaicism in samples is not recom-
mended. As with aCGH, NGS cannot directly detect bal-
anced chromosomal rearrangements, because there is no
imbalance in the total DNA content.
Other limitations include higher cost and time-
consuming. Currently, NGS-based PGS cost per sample
is about $10–20 more expensive than aCGH-based PGS.
This may be mainly due to the early stage of this tech-
nology in human IVF-PGS. As NGS cost has been de-
creased significantly during the past couple of years
from a few thousand dollars per sample to a few hun-
dred dollars per sample now, it is believed that the cost
will keep reducing in the future. Thus the cost may be
less than aCGH-based PGS in near future.
The time for aCGH-based PGS has recently be reduced
from about 20 hrs to current 8 hrs by reducing the time
for DNA hybridization, this makes fresh embryo transfer
to be possible if the test is on site or samples are biopsied
from day 3 embryos [28]. However, NGS generally takes
about 14 hrs due to time-consuming of DNA sequencing.
Even so, it is still within a time frame compatible with a
fresh embryo transfer if biopsy is done on day 3 and trans-
fer is done on day 5 or day 6 [28]. However, recently, a
tendency to freeze all embryos has been adopted in
Northern America and other countries due to a better
patient management, high embryo freeze/thawing survival
rate and better embryo implantation rate per transfer,
such a time frame between testing and frozen embryo
transfer may not significantly limit the implementation of
this technology to embryos at blastocyst stage.
Conclusions
In conclusion, the present study was intended to be a pre-
liminary preclinical evaluation, providing proof of feasibility
for a new technology called VeriSeq NGS used for PGS.
The comprehensive chromosome screening method de-
scribed overcomes many of the problems that limited
earlier aneuploidy screening techniques and may finally
allow NGS-PGS to achieve the benefits predicted by theory.
NGS can provide rapid PGS results with a high level of ac-
curacy and more cost-effective than established methodolo-
gies in near future. Prospective clinical studies with large
number of embryo biopsy specimens from patients will be
implemented to obtain a larger sequencing dataset and
more evidence for the extensive use of NGS-based PGS.
Methods
Samples and sample amplification
Forty three human embryo TE biopsy samples with
known karyotype (41 abnormal and 2 normal) and 5
Fig. 3 Incidence of the errors of individual chromosomes. The x-axis indicates the chromosome number, and the y-axis indicates the incidence of
the chromosome errors. The abnormalities occurred to almost all chromosomes, except chromosome 6, 7, 17 and Y chromosome
Zheng et al. Molecular Cytogenetics  (2015) 8:38 Page 7 of 9
cytogenetically characterized cell lines (Coriell Cell
Repositories) were tested. For whole genome amplification
(WGA), TE cell samples and negative controls were col-
lected in 2 μl of PBS buffer, lysed with 2 μl of SurePlex cell
extraction buffer and 5 μl of the SurePlex Extraction cock-
tail master mix and then incubated at 75 °C for 10 min
followed by further incubation at 95 °C for 4 min. Then
genomic DNA (gDNA) was randomly fragmented by add-
ing 5 μl of SurePlex Pre-amplification cocktail to the lysed
biopsy samples or to gDNA controls and the mixture was
incubated according to the following protocol: one cycle
of 95 °C for 2 min, followed by 12 cycles of 95 °C for
15 seconds, 15 °C for 50 seconds, 25 °C for 40 seconds,
35 °C for 30 seconds, 65 °C for 40 seconds and 75 °C for
40 seconds, followed by a hold at 4 °C. Thereafter, gDNA
was amplified using the PicoPLEX WGA Kit (NEB) ac-
cording to the following thermal cycler program: one cycle
of 95 °C for 2 min, followed by 14 cycles of 95 °C for
15 seconds, 65 °C for 1 min and 75 °C for 1 min, followed
by a hold at 4 °C. To determine the success of the amplifi-
cation, 5 μl of each amplified sample plus 5 μl gel loading
buffer were examined by electrophoresis on a 1.5 % agar-
ose TBE gel.
The same amplified samples were processed with both
NGS protocol and aCGH protocol for aneuploidy status.
Discordant samples were subsequently reevaluated by a
third methodology, quantitative fluorescent polymerase
chain reaction (QF-PCR), following the protocol de-
scribed elsewhere [29]. When QF-PCR confirmed one of
the initial methods, the remaining discordant method
was considered to have delivered an erroneous result.
NGS with VeriSeq PGS protocol
Amplified samples for NGS were processed with VeriSeq
PGS kit (Illumina). DNA ‘indexing’ was performed in
order to simultaneously analyze samples from different
embryos, using the Nextera XT 96 - Index Kit (Illumina,
Inc.). In brief, amplified samples were diluted and concen-
tration was measured with Qubit dsDNA HS assay kit
(Life technology). One nanogram total amplified DNA at
0.2 ng/ml of each sample was tagmented (tagged and frag-
mented) by the VeriSeq PGS transposome with manufac-
ture’s protocol. The tagmentation step was carried out at
55 °C for 5 min and hold at 10 °C. The resulting tagmen-
ted mixture was neutralized by adding 5 ml of proprietary
neutralization buffer. Post-homogenization, the Tagmenta-
tion plate was held at room temperature for 5 min.
The tagmented DNA was amplified with index primer
(i7) and (i5) to become the NGS library via a limited-
cycle PCR program (one cycle of 72 °C for 3 min,
followed by 12 cycles of 95 °C for 10 seconds, 55 °C for
30 seconds and 72 °C for 30 seconds, one cycle at 72 °C
for 30 seconds, followed by a hold at 4 °C). Each sam-
ple’s NGS library was purified with no salt carryover,
providing a size selection step that removes short library
fragments including index 1 (i7) and index 2 (i5) from
the population. Finally 24 samples NGS library were
pooled and loaded to the VeriSeq PGS (Illumina) se-
quencing cartridge following manufacture’s protocol.
NGS library was sequenced with Illumina Miseq system.
Sequencing data were generated by MiSeq Reporter
Software. The following bioinformatics analysis was
accomplished with a pre-release version of BlueFuse
Multi for NGS (Illumina, Inc.). Each chromosome was
divided into intervals each approximately covering 1 Mb
of sequence. Filtered reads from each sample were then
mapped into the corresponding chromosome interval
or bin.
Agilent aCGH protocol
Thirteen microlitter of amplified samples were labeled
with Cy3 or Cy5 using SureTag DNA labeling kit (Agilent).
Labeled samples were combined and co-precipitated with
COT Human DNA in preparation for hybridization.
Labelled DNA was resuspended in dextran sulphate
hybridization buffer and loaded onto Agilent SurePrint
G3 human CGH 8 × 60 K oligo microarrays following
manufacture’s protocol. Reference DNA (both male and
female were used) for array was obtained from Promega
(Promega Corporation, Madison, WI USA). Thereafter,
the labelled products were hybridized to array slides.
After hybridization, arrays were washed to remove un-
bound labelled DNA and scanned with Agilent SureScan
scanner at 3 μM to excite the hybridized fluorophores read
and store the resulting images of the hybridization.
Scanned images were analyzed by Cytogenomics 2.7.8.0
software (Agilent) following manufacture’s protocol.
Human Genome Build 19 (hg19) was used in the present
study. Microarray chromosome information was named by
referring to Cytogenetic Nomenclatures ISCN 2013 [30].
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